[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"post-colonoscopy-gastrointestinal-symptoms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:post-colonoscopy-gastrointestinal-symptoms":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100632894",false,"NCT07519616","Effect of Escherichia Coli 5C (Colipral®) on Post-Colonoscopy Gastrointestinal Symptoms","Evaluation of the Effectiveness of Escherichia Coli 5C in the Management of Post-Colonoscopy Symptoms: A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial","Inclusion Criteria:\n\n* Age between 18 and 80 years\n* Complete diagnostic colonoscopy with achievement of the cecal fundus\n* Accepted written informed consent for study participation obtained prior to the start of the study\n\nExclusion Criteria:\n\n* Chronic inflammatory bowel disease\n* Complicated Diverticular Disease (DICA \\>3)\n* Suspected or known colorectal malignancy on index colonoscopy\n* Diagnosed microscopic colitis\n* Operative colonoscopy\n* Severe chronic gastrointestinal symptoms judged by the investigator to interfere with the evaluation of study endpoints\n* Subjects who are immunosuppressed or on systemic immunosuppressive treatment, including patients with primary or acquired immunodeficiency, oncological disease on active treatment with chemotherapy\u002Fimmunotherapy, or autoimmune diseases on immunosuppressive treatment\n* Taking probiotics, prebiotics, or synbiotics within 2-4 weeks prior to enrollment\n* Antibiotic therapy within 4 weeks prior to enrollment\n* Lack of acceptance of written informed consent","ALL","18 Years","80 Years",{"count":19,"type":20},160,"ESTIMATED","INTERVENTIONAL",[23],"NA","This prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial will evaluate the efficacy and safety of Escherichia coli 5C (Colipral®) in adult patients undergoing diagnostic colonoscopy. Participants will be randomized in a 1:1 ratio to receive either Colipral® or placebo for 14 days immediately after colonoscopy. The study aims to determine whether Colipral® reduces post-colonoscopy gastrointestinal symptoms compared with placebo, using validated symptom and stool assessment tools, patient-reported global improvement, and safety monitoring.",[26],"Post-Colonoscopy Gastrointestinal Symptoms","NOT_YET_RECRUITING","2026-04-02",{"date":30,"type":31},"2026-04-09","ACTUAL",{"date":33,"type":20},"2026-04-27",{"date":35,"type":20},"2026-10-30",{"name":37,"class":38},"Liaquat University of Medical & Health Sciences","OTHER",""]